440 related articles for article (PubMed ID: 25452729)
41. Heterodimerization of the kappa opioid receptor and neurotensin receptor 1 contributes to a novel β-arrestin-2-biased pathway.
Liu H; Tian Y; Ji B; Lu H; Xin Q; Jiang Y; Ding L; Zhang J; Chen J; Bai B
Biochim Biophys Acta; 2016 Nov; 1863(11):2719-2738. PubMed ID: 27523794
[TBL] [Abstract][Full Text] [Related]
42. Endogenous opiates and behavior: 2012.
Bodnar RJ
Peptides; 2013 Dec; 50():55-95. PubMed ID: 24126281
[TBL] [Abstract][Full Text] [Related]
43. Opioid reward mechanisms: a key role in drug abuse?
Herz A
Can J Physiol Pharmacol; 1998 Mar; 76(3):252-8. PubMed ID: 9673788
[TBL] [Abstract][Full Text] [Related]
44. Plasticity of Signaling by Spinal Estrogen Receptor α, κ-Opioid Receptor, and Metabotropic Glutamate Receptors over the Rat Reproductive Cycle Regulates Spinal Endomorphin 2 Antinociception: Relevance of Endogenous-Biased Agonism.
Liu NJ; Murugaiyan V; Storman EM; Schnell SA; Kumar A; Wessendorf MW; Gintzler AR
J Neurosci; 2017 Nov; 37(46):11181-11191. PubMed ID: 29025923
[TBL] [Abstract][Full Text] [Related]
45. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.
Jackson KJ; Carroll FI; Negus SS; Damaj MI
Psychopharmacology (Berl); 2010 Jun; 210(2):285-94. PubMed ID: 20232057
[TBL] [Abstract][Full Text] [Related]
46. Endogenous opiates and behavior: 2014.
Bodnar RJ
Peptides; 2016 Jan; 75():18-70. PubMed ID: 26551874
[TBL] [Abstract][Full Text] [Related]
47. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
48. Endogenous Opioid Dynorphin Is a Potential Link between Traumatic Brain Injury, Chronic Pain, and Substance Use Disorder.
Best KM; Mojena MM; Barr GA; Schmidt HD; Cohen AS
J Neurotrauma; 2022 Jan; 39(1-2):1-19. PubMed ID: 34751584
[TBL] [Abstract][Full Text] [Related]
49. Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell.
Svingos AL; Colago EE; Pickel VM
J Neurosci; 1999 Mar; 19(5):1804-13. PubMed ID: 10024364
[TBL] [Abstract][Full Text] [Related]
50. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses.
McLaughlin JP; Marton-Popovici M; Chavkin C
J Neurosci; 2003 Jul; 23(13):5674-83. PubMed ID: 12843270
[TBL] [Abstract][Full Text] [Related]
51. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons.
Margolis EB; Hjelmstad GO; Bonci A; Fields HL
J Neurosci; 2003 Nov; 23(31):9981-6. PubMed ID: 14602811
[TBL] [Abstract][Full Text] [Related]
52. Dynorphin and κ-Opioid Receptor Dysregulation in the Dopaminergic Reward System of Human Alcoholics.
Bazov I; Sarkisyan D; Kononenko O; Watanabe H; Yakovleva T; Hansson AC; Sommer WH; Spanagel R; Bakalkin G
Mol Neurobiol; 2018 Aug; 55(8):7049-7061. PubMed ID: 29383684
[TBL] [Abstract][Full Text] [Related]
53. Species differences in the effects of the κ-opioid receptor antagonist zyklophin.
Sirohi S; Aldrich JV; Walker BM
Alcohol; 2016 Mar; 51():43-9. PubMed ID: 26992699
[TBL] [Abstract][Full Text] [Related]
54. The dynorphin/kappa opioid receptor mediates adverse immunological and behavioral outcomes induced by repetitive blast trauma.
Lee SJ; Logsdon AF; Yagi M; Baskin BM; Peskind ER; Raskind MM; Cook DG; Schindler AG
J Neuroinflammation; 2022 Dec; 19(1):288. PubMed ID: 36463243
[TBL] [Abstract][Full Text] [Related]
55. Nicotine and endogenous opioids: neurochemical and pharmacological evidence.
Hadjiconstantinou M; Neff NH
Neuropharmacology; 2011 Jun; 60(7-8):1209-20. PubMed ID: 21108953
[TBL] [Abstract][Full Text] [Related]
56. Imaging Kappa Opioid Receptors in the Living Brain with Positron Emission Tomography.
Placzek MS
Handb Exp Pharmacol; 2022; 271():547-577. PubMed ID: 34363128
[TBL] [Abstract][Full Text] [Related]
57. A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain.
Edwards KA; Havelin JJ; Mcintosh MI; Ciccone HA; Pangilinan K; Imbert I; Largent-Milnes TM; King T; Vanderah TW; Streicher JM
J Pain; 2018 Jun; 19(6):612-625. PubMed ID: 29371114
[TBL] [Abstract][Full Text] [Related]
58. A Trigger for Opioid Misuse: Chronic Pain and Stress Dysregulate the Mesolimbic Pathway and Kappa Opioid System.
Massaly N; Morón JA; Al-Hasani R
Front Neurosci; 2016; 10():480. PubMed ID: 27872581
[TBL] [Abstract][Full Text] [Related]
59. Alcohol-induced plasticity in the dynorphin/kappa-opioid receptor system.
Sirohi S; Bakalkin G; Walker BM
Front Mol Neurosci; 2012; 5():95. PubMed ID: 23060746
[TBL] [Abstract][Full Text] [Related]
60. Kappa opioid receptor antagonism protects working memory performance from mild stress exposure in Rhesus macaques.
Wallace TL; Martin WJ; Arnsten AFT
Neurobiol Stress; 2022 Nov; 21():100493. PubMed ID: 36532373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
